利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.032 秒)

    Benzamide compounds and pharmaceutical use thereof
    5.
    发明授权
    Benzamide compounds and pharmaceutical use thereof 有权
    苯甲酰胺化合物及其药物用途

    公开(公告)号：US6156766A

    公开(公告)日：2000-12-05

    申请号：US252079

    申请日：1999-02-18

    申请人： Masafumi Arita ,  Tadamasa Saitoh ,  Masanori Minoguchi ,  Keiji Yamagami ,  Hiroyuki Satoh

    发明人： Masafumi Arita ,  Tadamasa Saitoh ,  Masanori Minoguchi ,  Keiji Yamagami ,  Hiroyuki Satoh

    IPC分类号： A61P9/12 ,  C07D213/75 ,  C07D213/82 ,  C07D215/42 ,  C07D239/42 ,  C07D239/48 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04 ,  A61K31/437 ,  A61K31/519

    CPC分类号： C07D213/75 ,  C07D213/82 ,  C07D215/42 ,  C07D239/42 ,  C07D239/48 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D473/34 ,  C07D487/04

    摘要： Benzamide compounds of the formula ##STR1## wherein each symbol is defined in the specification, isomers thereof and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions comprising a therapeutically effective amount of this compound and a pharamaceutically acceptable additive, and therapeutic agents for hypertension, therapeutic agents for angina pectoris, therapeutic agent for asthma, therapeutic agents for renal and peripheral circulatory disturbances and inhibitor of cerebral vasospasm, which comprise this compound. The compound of the present invention has strong smooth muscle relaxing action, and shows hypertensive action and cerebral.cndot.coronary vasodilating action like conventional calcium antagonists, as well as long-lasting renal and peripheral circulation improving action. Unlike calcium antagonists, it permits oral administration to suppress vascular contraction caused by various agonists, and is useful as a strong and long-acting agent for prophylaxis and treatment of circulatory diseases in coronary, cerebral, renal and peripheral arteries, as a therapeutic agent for hypertension, angina pectoris, and renal and peripheral circulation disorder, an inhibitor of cerebral vasospasm and the like. Moreover, the compound of the present invention is useful as a therapeutic agent for asthma.

    摘要翻译： 具有下式的苯甲酰胺化合物其中每个符号在说明书中定义，其异构体和其药学上可接受的酸加成盐。 包含治疗有效量的该化合物和药学上可接受的添加剂的药物组合物，高血压治疗剂，心绞痛治疗剂，哮喘治疗剂，肾脏和外周循环障碍治疗剂以及脑血管痉挛抑制剂，其包含 复合。 本发明的化合物具有强的平滑肌松弛作用，并且显示出与常规钙拮抗剂相似的高血压作用和脑血管舒张作用，以及持久的肾脏和外周循环改善作用。 与钙拮抗剂不同，它允许口服给药以抑制由各种激动剂引起的血管收缩，并且可用作预防和治疗冠状动脉，脑，肾和外周动脉中的循环系统疾病的强力和长效剂，作为治疗剂 高血压，心绞痛，肾和周围循环障碍，脑血管痉挛抑制剂等。 此外，本发明的化合物可用作哮喘的治疗剂。

    Remedy for sleep disturbance
    6.
    发明授权
    Remedy for sleep disturbance 失效
    解决睡眠障碍

    公开(公告)号：US08003669B2

    公开(公告)日：2011-08-23

    申请号：US12453057

    申请日：2009-04-28

    申请人： Koji Teshima ,  Masanori Minoguchi

    发明人： Koji Teshima ,  Masanori Minoguchi

    IPC分类号： A61K31/454

    CPC分类号： C07D401/04 ,  A61K31/00 ,  A61K31/454 ,  A61K31/527

    摘要： The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more particularly, an agent for the prophylaxis and/or treatment of a sleep disorder, which contains an ORL-1 receptor agonist, and a novel compound useful as such agent for the prophylaxis and/or treatment.

    摘要翻译： 本发明是基于以作为激动剂作用于ORL-1受体的化合物作为非光学夹带因子的化合物的发现而进行的，并且促进了昼夜节律期，并且提供了一种用于睡眠障碍的新型治疗剂， 作为昼夜节律睡眠障碍，更具体地，涉及含有ORL-1受体激动剂的睡眠障碍的预防和/或治疗药物，以及可用作预防和/或治疗剂的新型化合物。

    Remedy for sleep disturbance
    8.
    发明申请
    Remedy for sleep disturbance 失效
    解决睡眠障碍

    公开(公告)号：US20050119308A1

    公开(公告)日：2005-06-02

    申请号：US10508339

    申请日：2003-03-28

    申请人： Koji Teshima ,  Masanori Minoguchi

    发明人： Koji Teshima ,  Masanori Minoguchi

    IPC分类号： A61K31/00 ,  A61K31/454 ,  A61K31/527 ,  A61P25/20 ,  C07D401/04 ,  C07D43/04

    CPC分类号： C07D401/04 ,  A61K31/00 ,  A61K31/454 ,  A61K31/527

    摘要： The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more particularly, an agent for the prophylaxis and/or treatment of a sleep disorder, which contains an ORL-1 receptor agonist, and a novel compound useful as such agent for the prophylaxis and/or treatment.

    摘要翻译： 本发明是基于以作为激动剂作用于ORL-1受体的化合物作为非光学夹带因子的化合物的发现而进行的，并且促进了昼夜节律期，并且提供了一种用于睡眠障碍的新型治疗剂， 作为昼夜节律睡眠障碍，更具体地，涉及含有ORL-1受体激动剂的睡眠障碍的预防和/或治疗药物，以及可用作预防和/或治疗剂的新型化合物。